• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

全国肺动脉高压相关住院患者的趋势和住院结局——基于全国住院患者样本数据库的分析。

National trends and inpatient outcomes of pulmonary arterial hypertension related hospitalizations - Analysis of the National Inpatient Sample Database.

机构信息

Department of Internal Medicine, Allegheny General Hospital, Pittsburgh, PA, United States.

Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, PA, United States.

出版信息

Int J Cardiol. 2020 Nov 15;319:131-138. doi: 10.1016/j.ijcard.2020.06.036. Epub 2020 Jun 27.

DOI:10.1016/j.ijcard.2020.06.036
PMID:32603739
Abstract

BACKGROUND

Pulmonary arterial hypertension (PAH) is associated with a significant burden of morbidity and mortality. We examined national trends in PAH-related hospitalizations, associated inpatient mortality (IM), length of stay (LOS) and hospitalization charges from 2007 to 2016, as well as predictors of IM and LOS in this population.

METHODS

We used the National Inpatient Sample to identify PAH admissions using International classification of diseases (ICD) codes 416.0 (ICD-9) and I27.0 (ICD-10). Records suggestive of secondary causes of pulmonary hypertension were excluded. 6162 (weighted) records with PAH as the primary diagnosis were analyzed.

RESULTS

Mean age was 38.7 years, with the majority being females (78.8%). Overall IM was 6.03%, mean LOS 7.6 ± 0.5 days and mean charges $84,100 ± 6200. PAH-related hospitalizations (per million) (27 in 2007 vs. 28 in 2016, p = 0.19) and associated IM (4.5% in 2007 vs. 6.8% in 2016, p = 0.748) as well as LOS (5.9 days in 2007 vs 6.7 days in 2016, p = 0.304) remained unchanged over the decade. Charges increased by 2.4-fold ($43,800 in 2007 to $103,300 in 2016, p = 0.002). While right heart failure, fluid/electrolyte disorders, cardiac arrhythmia and neurological disorders were associated with increased IM, Hispanic race was found to have a survival benefit. Fluid/electrolyte disorders and coagulopathy were associated with increased LOS.

CONCLUSION

Despite significant advancements in PAH therapies over the duration of this study, the rate of PAH hospitalizations, and associated IM and LOS remain unchanged. The study identified the predictors of IM and prolonged LOS in PAH population which could be used for additional risk stratification of these patients.

摘要

背景

肺动脉高压(PAH)与发病率和死亡率的显著负担有关。我们研究了 2007 年至 2016 年期间与 PAH 相关的住院治疗、相关住院死亡率(IM)、住院时间(LOS)和住院费用的国家趋势,以及该人群中 IM 和 LOS 的预测因素。

方法

我们使用国家住院患者样本,使用国际疾病分类(ICD)第 416.0 条(ICD-9)和 I27.0 条(ICD-10)识别 PAH 入院病例。排除提示肺动脉高压继发性原因的记录。分析了 6162 条(加权)以 PAH 为主要诊断的记录。

结果

平均年龄为 38.7 岁,大多数为女性(78.8%)。总体 IM 为 6.03%,平均 LOS 为 7.6 ± 0.5 天,平均费用为 84100 ± 6200 美元。PAH 相关住院治疗(每百万)(2007 年为 27 例,2016 年为 28 例,p=0.19)和相关 IM(2007 年为 4.5%,2016 年为 6.8%,p=0.748)以及 LOS(2007 年为 5.9 天,2016 年为 6.7 天,p=0.304)在这十年中保持不变。费用增加了 2.4 倍(2007 年为 43800 美元,2016 年为 103300 美元,p=0.002)。虽然右心衰竭、液体/电解质紊乱、心律失常和神经系统疾病与 IM 增加有关,但发现西班牙裔种族具有生存优势。液体/电解质紊乱和凝血障碍与 LOS 延长有关。

结论

尽管在这项研究期间 PAH 治疗取得了重大进展,但 PAH 住院治疗率以及相关的 IM 和 LOS 仍然保持不变。该研究确定了 PAH 人群中 IM 和延长 LOS 的预测因素,可用于对这些患者进行额外的风险分层。

相似文献

1
National trends and inpatient outcomes of pulmonary arterial hypertension related hospitalizations - Analysis of the National Inpatient Sample Database.全国肺动脉高压相关住院患者的趋势和住院结局——基于全国住院患者样本数据库的分析。
Int J Cardiol. 2020 Nov 15;319:131-138. doi: 10.1016/j.ijcard.2020.06.036. Epub 2020 Jun 27.
2
Pulmonary arterial hypertension in systemic sclerosis: a national inpatient analysis.系统性硬皮病中的肺动脉高压:一项全国性住院患者分析。
ARP Rheumatol. 2024 Apr-Jun;3(2):95-100.
3
Trends and Outcomes of Pulmonary Arterial Hypertension-Related Hospitalizations in the United States: Analysis of the Nationwide Inpatient Sample Database From 2001 Through 2012.美国肺动脉高压相关住院治疗的趋势与结果:对2001年至2012年全国住院患者样本数据库的分析
JAMA Cardiol. 2016 Dec 1;1(9):1021-1029. doi: 10.1001/jamacardio.2016.3591.
4
Inpatient Palliative Care Use in Patients With Pulmonary Arterial Hypertension: Temporal Trends, Predictors, and Outcomes.肺动脉高压患者住院姑息治疗的使用:时间趋势、预测因素和结果。
Chest. 2020 Dec;158(6):2568-2578. doi: 10.1016/j.chest.2020.07.079. Epub 2020 Aug 12.
5
Nationwide trends in inpatient admissions of pulmonary hypertension in the United States from 2000 to 2013.2000年至2013年美国肺动脉高压住院患者的全国性趋势。
Adv Respir Med. 2017;85(2):77-86. doi: 10.5603/ARM.2017.0014.
6
Primary cardiac hospitalizations in pulmonary arterial hypertension: Trends and outcomes from 2001 to 2014.原发性肺动脉高压患者的心脏住院情况:2001 年至 2014 年的趋势和结果。
Respir Med. 2020 Jan;161:105850. doi: 10.1016/j.rmed.2019.105850. Epub 2019 Nov 28.
7
Characterizing pulmonary hypertension-related hospitalization costs among Medicare Advantage or commercially insured patients with pulmonary arterial hypertension: a retrospective database study.对医疗保险优势计划参保者或商业保险覆盖的肺动脉高压患者的肺动脉高压相关住院费用进行特征分析:一项回顾性数据库研究。
Am J Manag Care. 2015 Jan;21(3 Suppl):s47-58.
8
Gender and Racial Differences in Hospitalizations for Primary Biliary Cholangitis in the USA.美国原发性胆汁性胆管炎住院治疗的性别和种族差异。
Dig Dis Sci. 2021 May;66(5):1461-1476. doi: 10.1007/s10620-020-06402-3. Epub 2020 Jun 13.
9
Predictors of outcomes and hospital charges following atlantoaxial fusion.寰枢椎融合术后的预后及住院费用预测因素。
Spine J. 2016 May;16(5):608-18. doi: 10.1016/j.spinee.2015.12.090. Epub 2016 Jan 11.
10
Temporal Trends for Patients Hospitalized With Atrial Fibrillation in the United States: An Analysis From the National Inpatient Sample (NIS) Database 2011-2018.美国心房颤动住院患者的时间趋势:来自2011 - 2018年国家住院样本(NIS)数据库的分析
Cureus. 2022 Jun 6;14(6):e25694. doi: 10.7759/cureus.25694. eCollection 2022 Jun.

引用本文的文献

1
Exploring the Economic Burden of Pulmonary Arterial Hypertension and Its Relation to Disease Severity and Treatment Escalation: A Systematic Literature Review.探索肺动脉高压的经济负担及其与疾病严重程度和治疗升级的关系:一项系统文献综述
Pharmacoeconomics. 2025 Apr 17. doi: 10.1007/s40273-025-01492-1.
2
Economic Burden Associated with Pulmonary Arterial Hypertension in the United States.美国肺动脉高压相关的经济负担
Pharmacoeconomics. 2025 Jan;43(1):83-91. doi: 10.1007/s40273-024-01427-2. Epub 2024 Oct 12.
3
Inhaled treprostinil vs iloprost: Comparison of adherence, persistence, and health care resource utilization in patients with pulmonary arterial hypertension.
吸入性曲前列尼尔与伊洛前列素:肺动脉高压患者在药物依从性、持续治疗和医疗资源利用方面的比较。
J Manag Care Spec Pharm. 2023 Jan;29(1):101-108. doi: 10.18553/jmcp.2023.29.1.101.
4
Management of COVID-19 in Patients with Pulmonary Arterial Hypertension.COVID-19 患者的肺动脉高压管理。
Heart Fail Clin. 2023 Jan;19(1):107-114. doi: 10.1016/j.hfc.2022.07.003. Epub 2022 Aug 10.
5
Effect of Hospital Teaching Status on Mortality and Procedural Complications of Percutaneous Paracentesis in the United States: A Four-Year Analysis of the National Inpatient Sample.美国医院教学状况对经皮穿刺腹腔穿刺术死亡率和手术并发症的影响:对全国住院患者样本的四年分析
Cureus. 2022 Jun 24;14(6):e26282. doi: 10.7759/cureus.26282. eCollection 2022 Jun.
6
Bioactivities and mechanisms of natural medicines in the management of pulmonary arterial hypertension.天然药物在肺动脉高压治疗中的生物活性及作用机制
Chin Med. 2022 Jan 15;17(1):13. doi: 10.1186/s13020-022-00568-w.
7
Could Dual-Energy CT Become the "One-Stop Shop" Modality in Pulmonary Hypertension Workup?双能量CT能否成为肺动脉高压检查的“一站式”检查方式?
Radiol Cardiothorac Imaging. 2020 Dec 17;2(6):e200603. doi: 10.1148/ryct.2020200603. eCollection 2020 Dec.
8
Data on clinical and economic burden associated with pulmonary arterial hypertension related hospitalizations in the United States.美国肺动脉高压相关住院治疗的临床和经济负担数据。
Data Brief. 2020 Sep 11;32:106303. doi: 10.1016/j.dib.2020.106303. eCollection 2020 Oct.